Alkermes plc
ALKSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 30, 2026
Scan Results
Daily timeframeAlkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in. The $7.03B market capitalization puts ALKS squarely in mid-cap range for its industry. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Market Cap
$7.03B
Beta
0.26
P/E (TTM)
46.88
P/E (Fwd)
17.92
EPS (TTM)
$0.90
EPS (Fwd)
$2.35
ROE
9.4%
ROA
4.7%
Cash
$511.9M
Total Debt
$1.58B
Free CF
$140.6M
52W Change
34.8%
Annual Financials
Cash vs Debt
On the balance sheet, ALKS has $511.9M in cash with $1.58B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $140.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 9.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $1.11B to $1.48B.
The relatively low beta of 0.26 suggests ALKS is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alkermes plc and its sector.